COYA Strangle Strategy
COYA (Coya Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders.
COYA (Coya Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $100.1M, a beta of 0.62 versus the broader market, a 52-week range of 3.71-7.75, average daily share volume of 167K, a public-listing history dating back to 2022, approximately 8 full-time employees. These structural characteristics shape how COYA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.62 indicates COYA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on COYA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current COYA snapshot
As of June 30, 2026, spot at $5.95, ATM IV 242.30%, IV rank 49.76%, expected move 69.47%. The strangle on COYA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on COYA specifically: COYA IV at 242.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 69.47% (roughly $4.13 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated COYA expiries trade a higher absolute premium for lower per-day decay. Position sizing on COYA should anchor to the underlying notional of $5.95 per share and to the trader's directional view on COYA stock.
COYA strangle setup
The COYA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With COYA near $5.95, the first option leg uses a $6.25 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed COYA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 COYA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.25 | N/A |
| Buy 1 | Put | $5.65 | N/A |
COYA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
COYA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on COYA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on COYA
Strangles on COYA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the COYA chain.
COYA thesis for this strangle
The market-implied 1-standard-deviation range for COYA extends from approximately $1.82 on the downside to $10.08 on the upside. A COYA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current COYA IV rank near 49.76% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on COYA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, COYA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to COYA-specific events.
COYA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. COYA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move COYA alongside the broader basket even when COYA-specific fundamentals are unchanged. Always rebuild the position from current COYA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on COYA?
- A strangle on COYA is the strangle strategy applied to COYA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With COYA stock trading near $5.95, the strikes shown on this page are snapped to the nearest listed COYA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are COYA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the COYA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 242.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a COYA strangle?
- The breakeven for the COYA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current COYA market-implied 1-standard-deviation expected move is approximately 69.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on COYA?
- Strangles on COYA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the COYA chain.
- How does current COYA implied volatility affect this strangle?
- COYA ATM IV is at 242.30% with IV rank near 49.76%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.